Follitropin delta in IVF/ICSI programs
- Authors: Krasnopolskaya K.V.1,2, Isakova K.M.1, Ershova I.Y.1,2, Shostenko L.V.1, Shishkina A.V.1
-
Affiliations:
- Moscow Regional Research Institute of Obstetrics and Gynecology
- PRIOR CLINIC Reproductive Health Clinic
- Issue: No 12 (2022)
- Pages: 167-176
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/250598
- DOI: https://doi.org/10.18565/aig.2022.302
- ID: 250598
Cite item
Abstract
Keywords
Full Text
About the authors
Ksenia V. Krasnopolskaya
Moscow Regional Research Institute of Obstetrics and Gynecology; PRIOR CLINIC Reproductive Health Clinic
Email: guzmoniiag@gmail.com
Corresponding Member of the RAS, Dr. Med. Sci., Professor, Head of the Department of Reproductology
Kamila M. Isakova
Moscow Regional Research Institute of Obstetrics and Gynecology
Email: isa-kama@yandex.ru
PhD, obstetrician-gynecologist, Researcher
Irina Yu. Ershova
Moscow Regional Research Institute of Obstetrics and Gynecology; PRIOR CLINIC Reproductive Health Clinic
Email: i3236987@gmail.com
PhD, Researcher at the Department of Reproduction
Lidiya V. Shostenko
Moscow Regional Research Institute of Obstetrics and Gynecology
Email: lidsonnn@gmail.com
obstetrician-gynecologist, postgraduate student of the Department of Reproduction
Anna V. Shishkina
Moscow Regional Research Institute of Obstetrics and Gynecology
Email: anya.shostenko@yahoo.com
obstetrician-gynecologist, postgraduate student of the Department of Reproduction
References
- Von Wolff M. The role of natural cycle IVF in assisted reproduction. Best Pract. Res. Clin. Endocrinol. Metab. 2019; 33(1): 35-45. https://dx.doi.org/10.1016/j.beem.2018.10.005.
- Чеботникова Т.В. Гонадотропины: история создания. Вестник репродуктивного здоровья. 2008; 1-2: 78-9. https://dx.doi.org/10.14341/brh20081-278-79.
- Бекетова А.Н., Краснопольская К.В., Назаренко Т.А., Кабанова Д.И. Мочевые и рекомбинантные гонадотропины в программах ЭКО (обзор литературы). Проблемы репродукции. 2014; 3: 45 52.
- Olsson H., Sandstrom R., Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non human cell line. J. Clin. Pharmacol. 2014; 54(11): 1299-307. https://dx.doi.org/10.1002/jcph.328.
- Koechling W., Plaksin D., Croston G.E., Jeppesen J.V., Macklon K.T., Andersen C.Y. Comparative pharmacology of a new recombinant FSH expressed by a human cell line. Endocr. Connect. 2017; 6(5): 297-305. https://dx.doi.org/10.1530/EC-17-0067.
- Bissonnette F., Minano Masip J., Kadoch I.J., Librach C., Sampalis J., Yuzpe A. Individualized ovarian stimulation for in vitro fertilization: a multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin. Fertil. Steril. 2021; 115(4): 991-1000. https://dx.doi.org/10.1016/j.fertnstert.2020.09.158.
- Arce J.C., Larsson P., Garcia-Velasco J.A. Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa. Reprod. Biomed. Online. 2020; 41(4): 616-22. https://dx.doi.org/10.1016/j.rbmo.2020.07.006.
- Nyboe Andersen A., Nelson S.M., Fauser B.C., Garcia-Velasco J.A., Klein B.M., Arce J.C.; ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil. Steril. 2017; 107(2): 387-96. e4. https://dx.doi.org/10.1016/j.fertnstert.2016.10.033.
- Ishihara O., Arce J.C.; Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reprod. Biomed. Online. 2021; 42(5): 909-18. https://dx.doi.org/10.1016/j.rbmo.2021.01.023.
- La Marca A., Sunkara S.K. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum. Reprod. Update. 2014; 20(1): 124-40. https://dx.doi.org/10.1093/humupd/dmt037.
- Broer S.L., Broekmans F.J., Laven J.S., Fauser B.C. Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum. Reprod. Update. 2014; 20(5): 688-701. https://dx.doi.org/10.1093/humupd/dmu020.
- Zeng R., Chen H., Zeng X., Qin L. The essential role of body weight in adjusting Gn dosage to prevent high ovarian response for women with PCOS during IVF: a retrospective study. Front. Endocrinol. (Lausanne). 2022; 13: 922044. https://dx.doi.org/10.3389/fendo.2022.922044.
- Qiao J., Zhang Y., Liang X., Ho T., Huang H.Y., Kim S.H. et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum. Reprod. 2021; 36(9): 2452-62. https://dx.doi.org/10.1093/humrep/deab155.
- Ishihara O., Klein B.M., Arce J.C.; Japanese Follitropin Delta Phase 2 Trial Group. Randomized, assessor-blind, antimullerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertil. Steril. 2021; 115(6): 1478-86. https://dx.doi.org/10.1016/j.fertnstert.2020.10.059.
- Fernandez-Sanchez M., Visnova H., Yuzpe A., Klein B.M., Mannaerts B., Arce J.C.; ESTHER-1 and ESTHER-2 Study Group. Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles. Reprod. Biomed. Online. 2019; 38(4): 528-37. https://dx.doi.org/10.1016/j.rbmo.2018.12.032.
- Yacoub S., Cadesky K., Casper R.F. Low risk of OHSS with follitropin delta use in women with different polycystic ovary syndrome phenotypes: a retrospective case series. J. Ovarian Res. 2021; 14(1): 31. https://dx.doi.org/10.1186/s13048-021-00773-5.